Latest News Archive

Please select Category, Year, and then Month to display items

Health Sciences awards first Bongani Mayosi Medical Students Academic Prize

12 December 2020 | Story André Damons

Bongani Mayosi Prize Latest News — Drs Kaamilah Joosub (in front) and Lynette Upman, medical students in the Faculty of Health Sciences at the UFS, are the winners of the first Bongani Mayosi Medical Students Academic Prize for final-year medical students.

Two final-year medical students from the University of the Free State (UFS) became the first recipients of the prestigious Bongani Mayosi Medical Students Academic Prize which was bestowed on them 10 days before their graduation.

Drs Kaamilah Joosub and Lynette Upman, two final-year medical students in the Faculty of Health Sciences at the UFS are the first medical students from the university to be awarded the prize.This is the first year it has been awarded.

Drs Joosub and Upman received their awards at a function on Friday (4 December 2020) from Prof Hanneke Brits, Phase III chair and specialist in the Department of Family Medicine, on behalf of Prof Gert van Zyl, Dean of the Faculty of Health Sciences.

The Faculty of Health Sciences will host a virtual graduation on 14 December 2020.

Prestigious national award

The Bongani Mayosi Medical Students Academic Prize is a prestigious national award which aims to recognise final-year medical students who epitomise the academic, legendary, and altruistic life of Mayosi. The awards are presented to final-year MB ChB students from all South African medical faculties. Each student is allowed one vote for one classmate who, in their private opinion, best balances:

Academic achievement
Emotional intelligence ‑ good interpersonal skills
Social accountability ‑ the ability to respond helpfully to the needs of others

Winners are determined by the highest number of digital votes, with the first-prize winner receiving R6 000 and second prize coming in at R4 000.

Dr Lynette van der Merwe, undergraduate medical programme director in the School of Clinical Medicine at UFS, commented that Drs Joosub and Upman are worthy winners, as they have continuously exemplified the ideals recognised by this award during their undergraduate training.

The School of Clinical Medicine is very proud of its newest Kovsie doctors who successfully completed the academic year despite the immense challenges associated with the COVID-19 pandemic. This is thanks to the commitment and hard work of students and staff at the UFS.

Name behind the prize

The late Prof Bongani Mayosi was an outstanding doctor who rose rapidly through the ranks to become a top cardiologist, internationally recognised as a leading clinician scientist. He completed his undergraduate studies at the age of 22, having graduated cum laude in both the Bachelor of Medicine and Surgery (MB ChB) and Bachelor of Medical Sciences (BMedSci) degrees.

He trained as a physician and cardiologist at Groote Schuur Hospital and completed his doctorate at the University of Oxford in the UK. At the age of 38‚ he became the first black to be appointed professor and Head of the Department of Medicine at the University of Cape Town (UCT). In 2016, he was appointed Dean of the Faculty of Health Sciences at UCT. Before taking up his deanship, he completed the Advanced Management Programme at Harvard University in the US.

As a medical student Prof Mayosi excelled academically, was supportive of his classmates and enthusiastically involved in student residence committees and politics as well as community outreach programmes. As a researcher, he initiated an international programme of research focusing on solutions for poverty-related heart diseases and trained local clinician scientists and research leaders.

Prof Mayosi had an exceptional mixture of academic brilliance and vision; ambition and humility; kindness and generosity; passion and compassion; drive and empathy that complemented his ability to persuade and inspire others, which no doubt contributed to his 400 publications.

News Archive

Nuclear Medicine on the forefront of cancer research

2017-07-10

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma. The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept